- Home
- DMAC vs TLS Comparison
DMAC vs TLS Comparison
Compare DMAC & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- TLS
- Stock Information
- Founded
- DMAC 2000
- TLS 1969
- Country
- DMAC United States
- TLS United States
- Employees
- DMAC N/A
- TLS N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- TLS EDP Services
- Sector
- DMAC Health Care
- TLS Technology
- Exchange
- DMAC Nasdaq
- TLS Nasdaq
- Market Cap
- DMAC 260.0M
- TLS 209.4M
- IPO Year
- DMAC N/A
- TLS 2020
- Fundamental
- Price
- DMAC $4.45
- TLS $2.65
- Analyst Decision
- DMAC Strong Buy
- TLS Buy
- Analyst Count
- DMAC 4
- TLS 6
- Target Price
- DMAC $10.75
- TLS $3.94
- AVG Volume (30 Days)
- DMAC 393.5K
- TLS 640.9K
- Earning Date
- DMAC 08-06-2025
- TLS 08-11-2025
- Dividend Yield
- DMAC N/A
- TLS N/A
- EPS Growth
- DMAC N/A
- TLS N/A
- EPS
- DMAC N/A
- TLS N/A
- Revenue
- DMAC N/A
- TLS $109,269,000.00
- Revenue This Year
- DMAC N/A
- TLS $35.76
- Revenue Next Year
- DMAC N/A
- TLS $26.83
- P/E Ratio
- DMAC N/A
- TLS N/A
- Revenue Growth
- DMAC N/A
- TLS N/A
- 52 Week Low
- DMAC $3.19
- TLS $1.83
- 52 Week High
- DMAC $6.82
- TLS $4.82
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- TLS 41.01
- Support Level
- DMAC $4.81
- TLS $2.79
- Resistance Level
- DMAC $5.60
- TLS $2.93
- Average True Range (ATR)
- DMAC 0.49
- TLS 0.14
- MACD
- DMAC 0.05
- TLS -0.03
- Stochastic Oscillator
- DMAC 43.21
- TLS 5.24
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.